Evidence map›Paper›PMID 39019995›Full record

ArticleScientific reports2024

LncRNA HOXA-AS3 promotes cell proliferation and invasion via targeting miR-218-5p/FOXP1 axis in osteosarcoma.

Rong Li, Pingbo Chen, Yubo Zhou, Yi Lang, Changhui Zhou, Jingqin Ren, Adilijiang Maimaitiyimin, Zhen Chen, Chengqing Liu, Abasi Mainike and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Rong Li *College of Public Health, State Key Laboratory of Special Environment and Health Research in Xinjiang, Xinjiang Medical University, Urumqi, Xinjiang, China.
Pingbo Chen *Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi, 830017, Xinjiang, China.
Yubo Zhou *Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi, 830017, Xinjiang, China.
Yi Lang *Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi, 830017, Xinjiang, China.
Changhui ZhouCollege of Public Health, State Key Laboratory of Special Environment and Health Research in Xinjiang, Xinjiang Medical University, Urumqi, Xinjiang, China.
Jingqin RenCollege of Public Health, State Key Laboratory of Special Environment and Health Research in Xinjiang, Xinjiang Medical University, Urumqi, Xinjiang, China.
Adilijiang MaimaitiyiminXinjiang Medical University Affiliated Fifth Hospital, Urumqi, Xinjiang, China.
Zhen ChenCollege of Public Health, State Key Laboratory of Special Environment and Health Research in Xinjiang, Xinjiang Medical University, Urumqi, Xinjiang, China.
Chengqing LiuCollege of Public Health, State Key Laboratory of Special Environment and Health Research in Xinjiang, Xinjiang Medical University, Urumqi, Xinjiang, China.
Abasi MainikeXinjiang Medical University Affiliated Fifth Hospital, Urumqi, Xinjiang, China.
Lu Ding *Traditional Chinese Medicine Hospital Affiliated to Xinjiang Medical University, Urumqi, 830017, Xinjiang, China. dl_xjmu@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteosarcoma is an aggressive form of bone cancer and affects the health in children and adolescents. Although conventional treatment improves the osteosarcoma survival, some patients have metastasis and drug resistance, leading to a worse prognosis. Therefore, it is necessary to explore the molecular mechanism of osteosarcoma occurrence and progression, which could discover the novel treatment for osteosarcoma. Long noncoding RNAs (lncRNAs) have been reported to regulate osteosarcoma occurrence and malignant progression. LncRNA HOXA-AS3 facilitates the tumorigenesis and progression in a variety of human cancers. However, the underlying mechanism of lncRNA HOXA-AS3-induced oncogenesis is poorly determined in osteosarcoma. To address this point, we utilized several cellular biological strategies and molecular approaches to explore the biological functions and mechanisms of lncRNA HOXA-AS3 in osteosarcoma cells. We found that lncRNA HOXA-AS3 facilitates cell proliferation and invasion via targeting miR-218-5p/FOXP1 axis in osteosarcoma. In conclusion, lncRNA HOXA-AS3 could be a promising target for osteosarcoma treatment.

Indexed as

Bone NeoplasmsCell ProliferationForkhead Transcription FactorsGene Expression Regulation, NeoplasticMicroRNAsOsteosarcomaRepressor ProteinsRNA, Long NoncodingCell Line, TumorCell MovementHumansNeoplasm InvasivenessForkhead Transcription FactorsFOXP1 protein, humanMicroRNAsMIRN218 microRNA, humanRepressor ProteinsRNA, Long NoncodingFOXP1HOXA-AS3InvasionmiR-218-5pOsteosarcoma

Identifiers

PMID39019995
PMCPMC11254915

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.